Company attributes
Other attributes
Neos Therapeutics is a biopharmaceutical company developing, manufacturing, and commercializing extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms. Its area of focus is the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The company has three approved products for the treatment of ADHD in the market, Adzenys XR-ODT, Contempla XR-ODT, and Adzenys ER. Adzenys XR-ODT and Adzenys ER are central nervous system (CNS) stimulant prescription medicines used for the treatment of ADH in people 6 years of age and above. Contempla XR-ODT on the other hand, is for children aged 6 to 17 years old.
Neos also has the commercialization and profit rights to Generic Tussionex (Extended Release Hydrocodone Polistired/Chlorpheniramine Polistirex) from its collaboration partners, Chiesi USA and Coating Place. The product is indicated for the relief of cough and upper respiratory symptoms associated with allergy or colds in adults and children six years of age and above.
In its product pipeline, Neos has NT0400 and NR0501, which are treatments for nausea & vomitting and sialorrhea (excessive drooling), respectively. Both products are in the pre-clinical stages.
On June 9, 2011 Neos Therapeutics completed a venture capital round with $13.6 million in funding from undisclosed investors.
On November 24, 2009 Neos Therapeutics completed their series B funding round with $24.1 million in funding from undisclosed investors.
On March 4, 2014 Neos Therapeutics completed their series C funding round with $15.5 million in funding from Delaware Street Capital, Cabtree Partners, SMEA Capital, and Birrill & Company.
